Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EM-100
- Development stage
- Unknown
- Lead developer
- Eton Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
EM-100 is an investigational preservative-free ophthalmic solution containing ketotifen fumarate, developed for the temporary relief of ocular itching associated with allergic conjunctivitis. Initially developed by Eyemax LLC, its rights were acquired by Eton Pharmaceuticals and subsequently sold to Bausch Health, which launched it under the brand name Alaway® Preservative Free after FDA approval in September 2020. It functions as an antihistamine and mast cell stabilizer.
- Brand names
- Alaway® Preservative Free
- Other names
- ketotifen fumarate ophthalmic solutionketotifen fumarate
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on EM-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EM-100.